MAPT and Alzheimer disease: Furthermore, amyloid or tau biomarker results based on CSF, plasma, or PET were available and positive in 102 of 184 AD cases, whereas the remaining cases were diagnosed based on clinical‐neurological evaluation, neuropsychological assessment, MRI, and FDG PET.